Oncopeptides AB (publ) (ONCO.ST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Sofia Heigis M.Sc. | Chief Executive Officer | 5.96M | -- | 1980 |
| Prof. Rolf Larsson M.D., Ph.D. | Founder | -- | -- | -- |
| Prof. Rolf Lewensohn M.D., Ph.D. | Founder | -- | -- | -- |
| Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. | Founder | -- | -- | -- |
| Dr. Kristina Luthman Ph.D. | Founder | -- | -- | -- |
| Prof. Hans Ehrsson M.D. | Founder | -- | -- | -- |
| Mr. Peter Nygren | Founder | -- | -- | 1959 |
| Mr. Henrik Bergentoft | Chief Financial Officer | -- | -- | 1974 |
| Ms. Eva Nordström M.Sc., MSc Pharm | COO & Deputy MD | -- | -- | 1970 |
| Dr. Jakob Lindberg Med. Lic | Chief Scientific Officer | 4.82M | -- | 1972 |
Oncopeptides AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 80
Description
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Its PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The SPiKE platform designed to bind to both NK-cells and specific targets on various cancer cells. It is in late preclinical development for both solid tumors and hematologic malignancies. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Corporate Governance
Upcoming Events
May 15, 2025 at 6:00 AM UTC
Oncopeptides AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available